Personal Injury Law

Defective Drug Raptiva Recalled for Dangerous Side Effects

The U.S. Food and Drug Administration has announced that drug maker Genentech has withdrawn the psoriasis drug Raptiva from the market because of its link to drug related injury, one of which is a fatal brain infection. According to this news report, Raptiva could cause potential risk of patients developing progressive multifocal leukoencephalopathy or PML, which is a rare, serious, progressive neurological disease caused by a virus that affects the central nervous system.

Raptiva is an injection psoriasis patients take weekly to treat moderate to severe plaque psoriasis. Genentech estimates that 2,000 patients in the United States may be receiving Raptiva for chronic plaque psoriasis. FDA officials have told doctors nationwide not to initiate new Raptiva treatment and talk to their patients about alternative treatments and therapy.

All drugs have side effects, but when drugs cause serious or fatal side effects leaving you in worse shape than you were when you started treatment, something is horribly wrong. The New York pharmaceutical drug litigation lawyers at Wingate, Russotti & Shapiro, LLP, have represented numerous clients and their families over the years that have been injured by dangerous and defective drugs put on the market by drug manufacturers without proper testing or research.

If you are the victim of a defective or dangerous drug in New York, you could be entitled to compensation to cover medical expenses, additional treatment costs, pain and suffering, and loss of earnings. Please call us today to schedule your free consultation. We will remain on your side, fight for your legal rights and make sure that these drug makers are held accountable for their negligence.

Full post as published by New York Injury Talk Blog on May 18, 2009 (boomark / email).